Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Maughan

Showing results (1-10 of 111) with videos related to

Pageof 12
Sort By:
Clinical Advances in Hematology & Oncology : H&O|December 20, 2021
Combination therapy with radium-223 and enzalutamide in castration-resistant prostate cancerBenjamin L Maughan
Current Oncology Reports|April 19, 2022
Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022Benjamin L Maughan
Asian Journal of Andrology|June 17, 2021
New models for defining prostate cancer biology and patient prognosisJames Brundage, Benjamin L Maughan
Current Treatment Options in Oncology|July 5, 2023
Papillary Renal Cell Carcinoma: A Review of Prospective Clinical TrialsBenjamin L Maughan, Deepika Sirohi
Nature Reviews. Urology|February 13, 2020
Does sequencing order of antiandrogens in prostate cancer matter?Benjamin L Maughan, Emmanuel S Antonarakis
Expert Opinion on Pharmacotherapy|June 13, 2015
Androgen pathway resistance in prostate cancer and therapeutic implicationsBenjamin L Maughan, Emmanuel S Antonarakis
Expert Opinion on Pharmacotherapy|April 8, 2021
Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancerBenjamin L Maughan, Emmanuel S Antonarakis
Asian Journal of Andrology|August 27, 2014
Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for allBenjamin L Maughan, Emmanuel S Antonarakis
European Urology|April 9, 2016
A Potential Predictive Role for Prostate-specific Antigen Changes at 4 Weeks?Benjamin L Maughan, Mario A Eisenberger
Current Treatment Options in Oncology|November 6, 2015
Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate CancerBenjamin L Maughan, Emmanuel S Antonarakis
Pageof 12

Showing results (1-10 of 111) with videos related to

Sort By:
Pageof 12
Clinical Advances in Hematology & Oncology : H&O|December 20, 2021
Combination therapy with radium-223 and enzalutamide in castration-resistant prostate cancerBenjamin L Maughan
Current Oncology Reports|April 19, 2022
Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022Benjamin L Maughan
Asian Journal of Andrology|June 17, 2021
New models for defining prostate cancer biology and patient prognosisJames Brundage, Benjamin L Maughan
Current Treatment Options in Oncology|July 5, 2023
Papillary Renal Cell Carcinoma: A Review of Prospective Clinical TrialsBenjamin L Maughan, Deepika Sirohi
Nature Reviews. Urology|February 13, 2020
Does sequencing order of antiandrogens in prostate cancer matter?Benjamin L Maughan, Emmanuel S Antonarakis
Expert Opinion on Pharmacotherapy|June 13, 2015
Androgen pathway resistance in prostate cancer and therapeutic implicationsBenjamin L Maughan, Emmanuel S Antonarakis
Expert Opinion on Pharmacotherapy|April 8, 2021
Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancerBenjamin L Maughan, Emmanuel S Antonarakis
Asian Journal of Andrology|August 27, 2014
Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for allBenjamin L Maughan, Emmanuel S Antonarakis
European Urology|April 9, 2016
A Potential Predictive Role for Prostate-specific Antigen Changes at 4 Weeks?Benjamin L Maughan, Mario A Eisenberger
Current Treatment Options in Oncology|November 6, 2015
Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate CancerBenjamin L Maughan, Emmanuel S Antonarakis
Pageof 12